Meksifin, 50 mg/ml, solution for intravenous and intramuscular administration, 2 ml, 10 pcs.: instructions for use, reviews and analogues, prices in pharmacies. Buy and deliver to the nearest pharmacy or home in M

Mexifin, 50 mg/ml, solution for intravenous and intramuscular administration, 2 ml, 10 pcs.

Intramuscularly or intravenously (stream or drip).

When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.

The drug Meksifin® is administered slowly over 5–7 minutes in a stream, and dropwise at a rate of 40–60 drops per minute. The maximum daily dose should not exceed 1200 mg.

For acute cerebrovascular accidents

Meksifin® is used in the first 10–14 days - intravenous drip of 200–500 mg 2–4 times a day, then intramuscularly of 200–250 mg 2–3 times a day for 2 weeks.

For traumatic brain injury and consequences of traumatic brain injury

Meksifin® is used intravenously for 10–15 days at a dose of 200–500 mg 2–4 times a day.

For dyscirculatory encephalopathy in the decompensation phase

Meksifin® should be administered intravenously in a stream or drip at a dose of 200–500 mg 1–2 times a day for 14 days. Then intramuscularly at 100–250 mg/day over the next 2 weeks.

For vegetative dystonia syndrome

Meksifin® is prescribed intramuscularly at a dose of 50–400 mg per day for 14 days.

For course prophylaxis of dyscirculatory encephalopathy

Meksifin® is administered intramuscularly at a dose of 200–250 mg 2 times a day for 10–14 days.

For mild cognitive impairment in elderly patients and anxiety disorders

Meksifin® is used intramuscularly at a daily dose of 100–300 mg/day for 14–30 days.

In acute myocardial infarction as part of complex therapy

the drug Mexifin® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic drugs according to indications.

In the first 5 days, to achieve maximum effect, it is advisable to administer Mexifin® intravenously; in the next 9 days, Mexifin® can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or a 5% dextrose (glucose) solution in a volume of 100–150 ml for 30–90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible.

The drug is administered (intravenously or intramuscularly) 3 times a day, every 8 hours. The daily therapeutic dose is 9 mg/kg body weight per day, a single dose is 2–3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

For open-angle glaucoma of various stages as part of complex therapy

Meksifin® is administered intramuscularly at 100–300 mg/day, 1–3 times a day for 14 days.

For alcohol withdrawal syndrome

Meksifin® is administered in a dose of 200–500 mg intravenously or intramuscularly 2–3 times a day for 5–7 days.

In case of acute intoxication with antipsychotic drugs

Meksifin® is administered intravenously at a dose of 200–500 mg/day for 7–14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis)

the drug Meksifin® is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.

For acute edematous (interstitial) pancreatitis, the drug Meksifin® is prescribed 200–500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly. Mild severity of necrotizing pancreatitis -

100–200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Moderate severity
- 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution).
Severe course
- in a pulse dosage of 800 mg on the first day, with a two-fold administration regimen;
then 200–500 mg 2 times a day with a gradual reduction in the daily dose. Extremely severe course
- at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, after stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.

Mexicofin

Trade name of the drug: Mexifin® International nonproprietary name or generic name: Ethylmethylhydroxypyridine succinate

Chemical rational name: 2-ethyl-6-methyl-3-hydroxypyridine succinate

Dosage form: solution for intravenous and intramuscular administration

Composition: Active substance - ethylmethylhydroxypyridine succinate - 50 mg Excipient - water for injection - up to a volume of 1 ml

Description: Colorless or slightly colored transparent liquid

Pharmacological group: Antioxidant agent.

ATX code – N 07XX.

Pharmacological properties:

Pharmacodynamics. Meksifin belongs to the group of compounds of 3-hydroxypyridine and succinic acid and has antioxidant, antihypoxic, membrane-stabilizing, nootropic, stress-protective, anticonvulsant and anxiolytic effects.

Meksifin acts as an inhibitor of free radicals, inhibits the processes of lipid peroxidation, increases the activity of the antioxidant enzyme system, restores the structure and function of membranes impaired in various pathologies, has a modulating effect on membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholine diesterase), ion channels, receptor complexes, including benzodiazepine, GABA, acetylcholine, improves the transport of neurotransmitters, synaptic transmission and the relationship of brain structures. Increases dopamine levels in the brain.

The mechanism of action of mexifin is due to its ability to enhance the compensatory activation of aerobic glycolysis. It reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, increasing the content of ATP and creatine phosphate, and helps maintain the structural and functional organization of biomembranes.

Mexifin improves cerebral metabolism and blood supply to the brain, corrects disturbances in the regulatory and microcirculatory systems, suppressing constriction of arterioles and precapillaries, improves the rheological properties of blood, reducing platelet aggregation, stabilizing the membrane structures of blood cells (erythrocytes and platelets), preventing hemolysis, improves the functioning of the immune system. Meksifin has an antiatherogenic effect, causing regression of atherosclerotic changes in the arteries, reducing cholesterol and low-density lipoprotein levels, restoring lipid homeostasis.

Meksifin increases the performance and resistance of the body to the effects of various extreme damaging factors in oxygen-dependent pathological conditions (shock, stress, hypoxia and ischemia, cerebrovascular accidents, physical and mental overload), intoxication with alcohol and antipsychotics (neuroleptics).

Pharmacokinetics. With single and course use of mexifin, the maximum concentration in the blood plasma is achieved after 0.45 -0.5 hours. When administered at a dose of 400–500 mg, Cmax in blood plasma is 3.5–4 μg/ml. When administered intramuscularly, the drug is determined in the blood plasma for 4 hours. Pharmacokinetic profiles do not differ significantly with either single or continuous administration. It is excreted from the body in the urine mainly in the form of glucuron conjugates and in small quantities unchanged.

Indications for use: acute cerebrovascular accidents (as part of combination therapy), discirculatory encephalopathy, vegetative-vascular dystonia, mild cognitive disorders of atherosclerotic origin, anxiety disorders in neurotic and neurosis-like conditions, relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders , acute intoxication with antipsychotic drugs.

Contraindications:

Acute dysfunction of the liver and kidneys, increased individual sensitivity to the drug. Children's age, pregnancy, breastfeeding - due to insufficient knowledge of the effect of the drug in these categories of patients.

Directions for use and dosage:

Meksifin is prescribed intramuscularly or intravenously (stream or drip). Doses are selected individually. The duration of treatment and dosage regimen depend on the severity of the patient's condition and the effectiveness of treatment. Begin treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The maximum daily dose should not exceed 800 mg.

When administered by infusion, the drug should be diluted in physiological sodium chloride solution.

Mexifin is administered slowly over 5-7 minutes in a stream, and dropwise at a rate of 60 drops per minute.

Acute cerebrovascular accidents: as part of combination therapy, 200-300 mg intravenously in the first 2-4 days, then 100 mg intramuscularly 3 times a day. Course duration is 10-14 days.

Discirculatory encephalopathy (decompensation phase): 100 mg intravenously or drip 2-3 times a day for 14 days, then intramuscularly 100 mg per day for the next 14 days.

Prevention of dyscirculatory encephalopathy: intramuscularly 100 mg 2 times a day for 10-14 days.

Mild cognitive impairment in elderly patients and with anxiety disorders: intramuscularly 100-300 mg per day for 14-30 days.

Alcohol withdrawal syndrome: 100-200 mg intramuscularly 2-3 times a day or intravenously 1-2 times a day for 5-7 days.

Acute intoxication with neuroleptics: intravenously 50-300 mg per day for 7-14 days, depending on the severity of the condition.

For neurotic disorders and vegetative-vascular dystonia, the drug is prescribed intramuscularly at a dose of 50-400 mg per day for 14 days.

Side effect:

Individual adverse reactions may occur: nausea and dry mouth, drowsiness, allergic reactions are possible.

Interaction with other drugs:

Potentiates the effect of benzodiazepine anxiolytics, anticonvulsants and antiparkinsonian drugs. The drug reduces the toxic effects of ethyl alcohol.

Special instructions:

At the beginning of treatment with the drug, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Currently, a number of drugs are produced with a similar active ingredient, ethylmethylhydroxypyridine succinate, which should be taken into account when treating other diseases in the treatment of which drugs containing this substance can be used.

Overdose.

In case of overdose, drowsiness may develop.

Release form:

Solution for intravenous and intramuscular administration 50 mg/ml. Ampoules 2ml or 5ml. 5 or 10 ampoules are placed in a blister pack. 1 or 2 blister packs along with instructions for medical use in a cardboard box.

Storage conditions:

List B. Store in a dry place, protected from light, out of reach of children, at a temperature not exceeding 25°C.

Best before date:

3 years. Do not use after the expiration date indicated on the package.

Vacation conditions:

On prescription.

Manufacturing company:

Federal State Unitary Enterprise Research and Production under the license of BrandPharma LLC.

Legal address and production address: 141400, Moscow region, Khimki, Vashutinskoe highway, 11, tel. +7 (495) 571 20 11

Organization accepting complaints:

BrandPharma LLC, 127521, Moscow, Maryinoy Roshchi 17th pr. 13.str.1, tel/fax

Registration number:

LS-001668

Trade name of the drug:

Mexiprim®

International nonproprietary or generic name:

Ethylmethylhydroxypyridine succinate

Chemical rational name:

3 - Hydroxy - 6 - methyl - 2 -ethylpyridine succinate

Dosage form:

solution for intravenous and intramuscular administration.

Composition per 1 ml

Ethylmethylhydroxypyridine succinate -50 mg Water for injection - up to 1 ml.

Description

Colorless or slightly yellowish transparent liquid.

Pharmacotherapeutic group

Antioxidant agent.

ATX code

N07XX

Pharmacological properties

Pharmacodynamics.

Mexiprim is a heteroaromatic antioxidant. It has a wide range of pharmacological activity: it increases the body’s resistance to stress, exhibits an anxiolytic effect that is not accompanied by drowsiness and a muscle relaxant effect; has nootropic properties, prevents and reduces learning and memory disorders that occur with aging and exposure to various pathogenic factors; has an anticonvulsant effect; exhibits antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol. The drug improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets). It has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins.

Mechanism of action

Mexiprim is due to its antioxidant and membrane protective effects. It inhibits lipid peroxidation, increases superoxide oxidase activity, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, transport of neurotransmitters and improve synaptic transmission. Mexiprim increases dopamine levels in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Pharmacokinetics.

The maximum concentration of Mexiprim in blood plasma ranges from 50 to 100 ng/ml. The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively. Mexiprim is intensively metabolized in the human body with the formation of its glucuron-conjugated product. On average, over 12 hours, 0.3% of the unchanged drug and 50% of the administered dose are excreted in the urine in the form of glucuronoconjugate. Mexiprim and its glucuronoconjugate are excreted most intensively during the first 4 hours after taking the drug. The urinary excretion rates of Mexiprim and its conjugated metabolite have significant individual variability.

Indications for use

Acute cerebrovascular accidents (as part of complex therapy);
Encephalopathy;
Vegetative-vascular dystonia;
Anxiety in neurotic and neurosis-like conditions;
Mild cognitive disorders of various origins (psycho-organic and asthenic syndromes, consequences of traumatic brain injuries, atherosclerosis, senile and atrophic processes, neuroinfections and intoxications);
Memory disorders and intellectual disability in the elderly;
Impact of extreme (stress) factors;
Withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
Acute intoxication with antipsychotic drugs.

Contraindications

Acute liver and/or renal failure, increased individual sensitivity to the drug. Children's age, pregnancy, breastfeeding - due to insufficient knowledge of the effect of the drug in these categories of patients.

Directions for use and doses

Mexiprim is prescribed intramuscularly or intravenously (stream or drip). Doses are selected individually. When administered by infusion, the drug should be diluted in physiological sodium chloride solution. Begin treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. Mexiprim is administered in a stream slowly over 5-7 minutes, drip-wise at a rate of 40-60 drops per minute. The maximum daily dose does not exceed 800 mg.

In case of acute cerebrovascular accidents, Mexiprim is used in complex therapy in the first 2-4 days intravenously at a dose of 200-300 mg once a day, then intramuscularly at a dose of 100 mg 3 times a day. The duration of treatment is 10-14 days.

For discirculatory encephalopathy in the decompensation phase, Mexiprim should be prescribed intravenously in a stream or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly at 100 mg 2-3 times a day over the next 2 weeks. For a course of prophylaxis of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days.

For mild cognitive impairment in elderly patients and anxiety disorders, the drug is used intramuscularly in a daily dose of 100-300 mg per day for 14-30 days.

For alcohol withdrawal syndrome, Mexiprim is administered in a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously 1-2 times a day for 5-7 days.

In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 50-300 mg per day for 7-14 days.

Side effect

Rarely - nausea, dry mouth, drowsiness, allergic reactions.

Overdose

Symptoms: sleep disturbance (insomnia, in some cases drowsiness). Treatment: as a rule, not required - symptoms disappear on their own within 24 hours. In severe cases of insomnia, it is recommended to take sleeping pills.

Interaction with other drugs

Mexiprim is compatible with psychotropic drugs; enhances the effect of benzodiazepine anxiolytics, antiparkinsonian drugs and carbamazepine. Reduces the toxic effect of ethyl alcohol.

special instructions

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Release form

Solution for intravenous and intramuscular administration 50 mg/ml. 2 ml or 5 ml in ampoules of neutral glass brand NS-3 or imported. 5 ampoules per blister pack made of polyvinyl chloride film and aluminum foil or packaging paper with a polymer coating, or without foil or coating.

1 or 2 blister packs (without foil or coating) with instructions for use of the drug, a knife or an ampoule scarifier in a cardboard pack.

20, 50 or 100 blister packs (for hospital use) with foil or coating, respectively, with 10, 25 or 50 instructions for use of the drug, knives or ampoule scarifiers in a cardboard box or corrugated cardboard box. When packaging ampoules with notches, rings or break points, scarifiers or ampoule knives are not used.

Storage conditions

List B. In a place protected from light at a temperature not exceeding 20 °C. Keep out of the reach of children.

Best before date